Mark Liberman is a Trustee Professor at the University of Pennsylvania , holding appointments in the Department of Linguistics and Department of Computer and Information Science . He serves as Director of the Linguistic Data Consortium and Faculty Director of Ware College House . His career spans linguistics, speech technology, and computational methods. Education: Harvard University (1965-1969), MIT (M.S. 1972, Ph.D. 1975) Professional Experience: AT&T Bell Laboratories (1975-1990), University of Pennsylvania (1990-present) His research interests include: Corpus-based Phonetics : Analyzing speech patterns via large-scale datasets. Clinical Applications : Developing speech biomarkers for neurodegenerative diseases. Tonal Phonology : Studying lexical tone and intonation in languages like Yoruba and Mandarin. Formal Annotation Models : Creating frameworks for linguistic data standardization. Recent publications highlight automated speech analysis, cross-linguistic prosody, and digital biomarkers for conditions like ALS-FTD and Alzheimer’s. His collaborations span computational linguistics , neurology , and cognitive science . Scientific awards include the IEEE James L. Flanagan Award (2017), Antonio Zampolli Prize (2010), and fellowships from the AAAS and Linguistic Society of America . He advises PhD students May Chan and Jonathan Him Nok Lee and contributes to editorial boards for journals like Cognition and Annual Review of Linguistics . His work bridges speech science , language technology , and neurocognitive research .
Daniel Finley is a Professor of Cell Biology at Harvard Medical School (HMS), leading the Finley Lab focused on the ubiquitin-proteasome pathway and related regulatory mechanisms. He holds academic appointments within the Department of Cell Biology and sits on the Scientific Advisory Boards of Proteostasis and X-Chem Pharmaceuticals. His research investigates proteasome function, ubiquitin-like proteins, and proteostasis roles in diseases like Alzheimer’s and ALS. Dr. Finley earned his undergraduate degree in biochemistry from Harvard University and a Ph.D. in molecular biology from MIT. After postdoctoral training at MIT, he joined HMS in 1988. His lab explores topics including erythroid proteome remodeling, mitochondrial dysfunction, and neurodegenerative disease mechanisms. Key research areas include: (1) Ubiquitin-proteasome pathway regulation, (2) Proteasome structure/function, (3) Nonproteolytic roles of ubiquitination, and (4) Pathophysiological roles of proteostasis defects in diseases. His work bridges basic cell biology with translational medicine, particularly in neurodegeneration and anemia. Finley has secured NIH funding for projects like 'Regulation of Proteasome Activity' (R35GM145246) and 'Erythrocyte maturation through global proteome remodeling' (R01HL153970). Collaborations with industry and academic partners extend his impact in drug discovery and proteasome-targeted therapies. His lab’s contributions include defining ubiquitin chain editing mechanisms, identifying USP14’s role in mitophagy, and elucidating proteostasis defects in Alzheimer's models. Research tools developed include advanced cryo-EM analyses of proteasomal structures and functional assays for ubiquitin system enzymes.
Dr. Catherine Legault serves as an Assistant Professor in the Department of Neurology and Neurosurgery at McGill University and Co-director of the Stroke Programme at the McGill University Health Centre. She is a neurologist at The Neuro (Montreal Neurological Institute-Hospital), a bilingual academic healthcare institution and part of McGill's Neuroscience Mission. Her educational background includes: Medical degree from McGill University (2011) Internship in Internal Medicine at Montreal’s Jewish General Hospital Neurology Residency at The Neuro (2012-2015) with chief residency (2014-2015) Vascular Neurology fellowship at Stanford University NIH StrokeNet fellowship Dr. Legault's clinical research focuses on translational stroke care, emphasizing acute interventions, rehabilitation innovation, and systems optimization. Her work integrates wearable technology with traditional stroke recovery methods while addressing post-stroke cognitive and visual impairments. She actively develops patient-centered educational frameworks and investigates hemodynamic interventions like induced hypertension. As principal investigator for multiple stroke clinical trials at The Neuro's Clinical Research Unit, she bridges bench-to-bedside research. Her teaching spans emergency consultations, bedside clinical supervision, and outpatient stroke clinics for residents and medical students. Through multidisciplinary collaboration in the Stroke Programme, Dr. Legault advances integrated care models that connect acute treatment with long-term rehabilitation, focusing on measurable functional outcomes and healthcare system efficiency.
Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.
Mayank R. Mehta is a Professor at the University of California, Los Angeles (UCLA), holding joint appointments in the Departments of Physics & Astronomy, Neurology, and Neurobiology. He is a member of the Brain Research Institute and the W. M. Keck Center for Neurophysics at UCLA. His research bridges experimental and theoretical neuroscience, focusing on how neuronal networks encode space-time, the role of brain rhythms in learning and memory, and the impact of sleep and virtual reality on neural dynamics. His recent publications highlight breakthroughs in understanding hippocampal spatiotemporal selectivity, dendritic activity during behavior, and the causal influence of visual cues on memory neurons. Notable findings include the discovery that dendrites generate ten times more spikes than neuronal cell bodies and the modulation of hippocampal theta rhythms in virtual reality. Research Themes: Neurophysics of spatial-temporal coding Dendritic contributions to learning Virtual reality and brain plasticity Neural oscillations in memory consolidation Key Collaborators: Bert Sakmann (Max Planck Florida Institute) Thomas Hahn (Bernstein Center Heidelberg/Mannheim) Maryam Ghorbani (UCLA) Mehta's lab at UCLA trains graduate and postdoctoral researchers in cutting-edge techniques combining hardware development, electrophysiological recordings, and biophysical modeling. His work has significant implications for treating learning and memory disorders like Alzheimer's disease.
David H. Sherman is the Hans W. Vahlteich Professor of Medicinal Chemistry at the University of Michigan, holding joint appointments in the College of Pharmacy (Department of Medicinal Chemistry), Medical School (Microbiology & Immunology), and College of Literature, Science, and the Arts (Chemistry). He leads the Sherman Lab at the Life Sciences Institute and co-founded the Natural Products Discovery Core. His research focuses on natural product discovery, biosynthetic pathways, and drug development for infectious diseases, cancer, and neurological disorders. Education: PhD in Synthetic Organic Chemistry from Columbia University (1981), BA in Chemistry from UC Santa Cruz (1978). Postdoctoral research at MIT (1984). Research interests include microbial secondary metabolites, enzymatic catalysis (e.g., C-H functionalization, polyketide assembly), and high-throughput drug screening. He pioneered a microbial natural product library with over 50,000 samples. Current projects emphasize developing macrolide antibiotics and advancing compounds toward clinical trials through the Natural Products Biosciences Initiative. Collaborations span global institutions, with a focus on biodiversity conservation and capacity-building in low-income nations. He has mentored 67 PhD students, 60 postdocs, and 85+ undergraduates, fostering interdisciplinary training in chemical biology and microbial biochemistry. Labs/Teams: Sherman Lab (Life Sciences Institute), Center Member at Samuel and Jean Frankel Cardiovascular Center, Center for Computational Medicine and Bioinformatics, Rogel Cancer Center.
Anirban Paul is an Associate Professor in the Department of Neuroscience and Experimental Therapeutics at Pennsylvania State University, affiliated with the Penn State Neuroscience Institute. His research focuses on cellular and molecular mechanisms of GABAergic inhibitory circuits, with particular emphasis on interneuron biology and its implications in neurological disorders. Dr. Paul's research spans multiple neuroscience domains, with primary focus on GABAergic inhibitory circuits and interneuron biology. His work investigates how specific neuron subtypes, particularly Chandelier cells and cortical interneurons, contribute to brain function and dysfunction. He has made significant contributions to understanding the role of these cells in schizophrenia, Alzheimer's disease, and other neurological conditions. His research integrates molecular, cellular, and systems-level approaches to uncover fundamental mechanisms of neural circuit assembly, plasticity, and function. Key areas include RNA regulation in neuronal development, transcriptomic subtypes of inhibitory neurons, and cell-type specific vulnerabilities in neurodegenerative diseases. His research portfolio demonstrates consistent productivity with publications spanning from 2003 to 2025, showing an evolving focus from basic molecular neuroscience to translational research in neurological disorders. Recent work emphasizes single-cell analysis techniques and the role of specific interneuron populations in disease mechanisms, particularly in schizophrenia and Alzheimer's disease. His publications appear in high-impact neuroscience journals including Neuron, BMC Biology, and Frontiers in Cellular Neuroscience. Dr. Paul has received the NARSAD Young Investigator Award (2018), recognizing his promising research in neuroscience. His scientific contributions have been supported by multiple competitive grants from prestigious organizations including the National Institute on Aging (NIA) and the Brain and Behavior Research Foundation. He serves as Principal Investigator on multiple active research projects, including two major grants from the National Institute on Aging focused on cell-type specific risk and resilience in Alzheimer's disease and aging (2021-2024 and 2024-2026), as well as previous projects from the Brain and Behavior Research Foundation investigating Chandelier cells in schizophrenia. His research program demonstrates sustained funding and scientific leadership in the field of interneuron biology and its clinical implications.
J. Anthony Movshon is a Professor at New York University (NYU) in the Department of Psychology and a key member of NYU's Center for Neural Science (CNS). His research focuses on the primate visual system, particularly the encoding and decoding of visual information in cortical areas like V1 and MT, and its role in behavior and perception. Education: Doctorate in Visual Neurophysiology and Psychophysics from Cambridge University Research Interests: Movshon investigates the functional architecture of the visual cortex, emphasizing motion, form, and color processing. His work explores how neural activity relates to perceptual decisions and motor behavior, using electrophysiological recordings, neuroimaging, and computational models. He also studies developmental disorders like amblyopia and their impact on visual system organization. Publications: His recent work spans visual texture selectivity in V2, contextual modulation in neural responses, motion processing in MT, and decoding mechanisms in visual cortex. These studies employ interdisciplinary approaches blending neurophysiology, computational neuroscience, and cognitive modeling. Labs & Collaborations: Movshon leads the Visual Neuroscience Laboratory at NYU, collaborating with researchers such as Michael Hawken, Lynne Kiorpes, and Eero Simoncelli.
Dr. Birgit Frauscher is the Lincoln Financial Group Distinguished Professor in Neurobiology at Duke University School of Medicine, where she serves as Professor of Neurology and holds a secondary appointment in the Department of Biomedical Engineering at the Duke Pratt School of Engineering. She is currently the Director of the Duke Comprehensive Epilepsy Center and leads the Analytical Neurophysiology (ANPHY) Lab. Her clinical and research work focuses on epilepsy and sleep medicine, utilizing both invasive and non-invasive electrical recordings to study brain activity in humans. Dr. Frauscher completed her medical training, neurology residency, and subspecialty training in electroencephalography, epilepsy, and sleep medicine at the Medical University of Innsbruck in Austria. After completing her clinical training in 2008, she earned her habilitation degree in 2011. She further specialized in intracranial EEG and signal analysis during a visiting professorship at the Montreal Neurological Institute and Hospital, McGill University (2013-2015), where she later served as an Attending Epileptologist and Group Leader of Epilepsy. Her research interests focus on developing novel seizure-independent EEG markers for the epileptogenic zone, investigating sleep-epilepsy interactions, and using intracranial EEG to study brain physiology during wakefulness and sleep. Her work aims to improve epilepsy diagnosis, prognosis, and treatment outcomes by better localizing the epileptic focus. Dr. Frauscher's recent publications demonstrate her continued leadership in epilepsy research, with over 170 peer-reviewed papers and an H-index of 62. Dr. Frauscher has received several prestigious awards including the Clinician-Scientist awards of the FRSQ (2018-2023), the Michael Prize of the International League against Epilepsy (2019), and the Ernst Niedermeyer Prize from the Austrian Epilepsy Society (2015). Her scholarly work has significantly advanced clinical knowledge in epilepsy and sleep medicine, establishing her as a leading figure in the field. As Director of the Duke Comprehensive Epilepsy Center and head of the ANPHY lab, Dr. Frauscher oversees a research program dedicated to advancing neuroscience through innovative approaches to studying brain activity. Her lab employs quantifiable tools to investigate neurophysiological and pathological processes related to epilepsy and sleep, with the ultimate goal of improving patient outcomes through better understanding of brain function.
Cristian Gómez Canela is a Full Professor in the Department of Analytical and Applied Chemistry at the School of Engineering, Ramon Llull University (IQS). He serves as Coordinator of the Master's Degree in Analytical Chemistry and is an active member of the Catalan Chemical Society (SCQ), representing SCQ in EuChems-EYCN. His academic journey includes a PhD in Chemistry from the University of Barcelona (2014), followed by postdoctoral research at IDAEA-CSIC and King's College University. Dr. Gómez Canela's research focuses on environmental analytical chemistry, particularly the optimization and validation of analytical methods based on liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) and high-resolution mass spectrometry (HRMS) for determining organic pollutants in environmental samples. His work extends to metabolomics applied to aquatic organisms and the analysis of neurotoxic compounds in water systems. His research fingerprint reveals strong expertise in zebrafish models (100%), neurotransmitter analysis (66%), Daphnia magna studies (64%), and neurotoxicity assessment (21%). His recent publications (2024-2025) demonstrate a clear trend toward environmental neurotoxicology, with emphasis on the effects of pharmaceuticals and industrial pollutants on aquatic organisms. His work integrates advanced analytical techniques with biological endpoints to assess environmental risks, particularly focusing on neurological and cardiovascular impacts. The research spans method development for pollutant detection, environmental monitoring, and mechanistic studies of neurotoxic effects. Dr. Gómez Canela leads multiple significant research projects including CHEMIPARK (2024-2027) on passive sampling methodologies for environmental pollutants, GESPA (2022-2025) as part of the Environmental Process Engineering and Simulation Group, and several projects on neuroactive compounds in water systems. He has an impressive research output with 91 scientific publications from 2011-2025 and an h-index of 27 with over 2,000 citations. As a dedicated educator, he contributes to multiple academic programs including the Master in Analytical Chemistry, Master in Pharmaceutical Chemistry, and undergraduate degrees in Chemistry and Chemical Engineering. His research group GESPA represents a multidisciplinary team combining chemical engineering, biotechnology, and chemical analysis to advance environmental sustainability through theoretical and experimental approaches.
Tanya P. Garcia, PhD is an Associate Professor of Biostatistics at the Gillings School of Public Health and Research Faculty in the UNC Neurology Huntington Disease Program at the University of North Carolina at Chapel Hill . She leads the Methods for INcomplete Data (MIND) Lab , focusing on statistical methods for handling censored, missing, or incomplete data in neurodegenerative disease progression studies. Education: PhD in Statistics, Texas A&M University MS in Statistics, University of Western Ohio MS in Industrial Engineering and Operations Research, UC Berkeley Research Interests: Specializing in High-Dimensional Variable Selection , Longitudinal Data Analysis , and Neurodegenerative Disease Modeling , her work develops reproducible statistical methods for Huntington's disease progression, improving clinical trial design and biomarker identification. Scientific Awards: American Statistical Association Fellow (2024) Landis Award for Outstanding Mentorship (2024) Roy R. Kuebler Award (2024) Gertrude M. Cox Award (2024) Leadership & Mentorship: Director of the MIND Lab, Chair-Elect of the Biometrics Section of ASA, and Tyson Academic Leadership Fellow (2023–2024). Her lab alumni have secured prestigious positions at institutions like Wake Forest University and Baylor University.
Marc V Fuccillo is an Associate Professor of Neuroscience at the Perelman School of Medicine, University of Pennsylvania, where he leads a research laboratory focused on understanding the neural circuit mechanisms underlying behavioral control. His work bridges molecular, synaptic, and behavioral approaches to investigate how striatal circuits regulate mouse behavior from simple motor patterns to complex goal-directed actions. Fuccillo holds dual appointments in the Neuroscience and Cell and Molecular Biology Graduate Groups at Penn and maintains an active laboratory investigating the synaptic and circuit basis of neuropsychiatric disorders. Education: B.A. in Molecular and Cellular Biology and Music Performance (Violin) from Brown University (1998) Ph.D. in Developmental Genetics from New York University School of Medicine (2007) M.D. from New York University School of Medicine (2008) Fuccillo's research centers on the synaptic and circuit mechanisms of behavioral control, with particular emphasis on striatal circuits. His laboratory employs a range of technologies including mouse genetics, in vitro electrophysiology, in vivo imaging, and quantitative behavioral analysis to explore how neural circuits of the striatum regulate behavior and how disruptions in these circuits contribute to neuropsychiatric disorders. His work has particularly focused on autism-associated abnormalities in behavioral control, examining how synaptic adhesion molecules like neuroligins and neurexins shape circuit function and behavior, with significant findings regarding D1 dopamine receptor positive medium spiny neurons in the nucleus accumbens. Analysis of Fuccillo's recent publications reveals a strong focus on striatal circuit function across multiple dimensions. His work spans molecular neuroscience (examining synaptic adhesion molecules), cellular physiology (studying specific neuron types in striatal circuits), systems neuroscience (mapping circuit connectivity), and behavioral neuroscience (quantifying motor learning and decision-making). A unifying theme is how disruptions in specific molecular pathways lead to circuit-level abnormalities that manifest as behavioral phenotypes relevant to neuropsychiatric disorders, with particular attention to autism, OCD, and schizophrenia models. Scientific Recognition: Publications in high-impact journals including Nature Neuroscience, Current Biology, Cell Reports, and Neuron Research supported by multiple NIH grants including NIMH F32, NIMH K01, and HHMI Gilliam Fellowship awards for lab members Fuccillo actively mentors a diverse group of trainees including postdoctoral fellows, graduate students, and undergraduates. His laboratory has produced numerous successful alumni who have gone on to faculty positions, medical residencies, and graduate programs at prestigious institutions. His mentoring approach emphasizes technical skill development across multiple neuroscience disciplines while fostering independent scientific thinking. Current research in his lab is supported by NIH funding focused on understanding the molecular architecture of striatal circuits and their role in behavioral control, with three major research directions exploring molecular logic of striatal circuits, circuit mechanisms of behavioral control, and striatal dysfunction in neuropsychiatric disease models. The Fuccillo Laboratory operates within the Department of Neuroscience at the University of Pennsylvania, with access to state-of-the-art facilities for molecular, electrophysiological, imaging, and behavioral neuroscience research. The lab maintains active collaborations with other neuroscience research groups at Penn and beyond, creating a rich intellectual environment for studying the neural basis of behavior. Current research directions include investigating whether there is a molecular logic to striatal circuit composition, how striatal circuits shape behavioral control, and what mouse models of autism, schizophrenia, and OCD can reveal about striatal circuit dysfunction in disease pathophysiology.
Dr. Steven G. Clarke is a Distinguished Professor at UCLA Department of Chemistry & Biochemistry and director of research at the Molecular Biology Institute . His work bridges protein chemistry , methylation biology , and aging research through studies of spontaneous protein damage and its repair mechanisms. Education: BA in Chemistry and Zoology, Pomona College (magna cum laude, Phi Beta Kappa) PhD in Biochemistry and Molecular Biology, Harvard University (NSF Fellow) Postdoctoral Fellowship at UC Berkeley (Miller Fellow) Dr. Clarke's research focuses on protein isoaspartyl repair via PCMT1/PIMT enzymes , ribosomal protein methylation in Saccharomyces cerevisiae , and PRMT family characterization including PRMT7 and PRMT9. His lab combines biochemical assays , genetic models , and structural analysis to investigate aging mechanisms and disease implications. Recent publications highlight: COQ5 structure-function analysis in coenzyme Q biosynthesis PCMTD1 ubiquitin ligase interactions PRMT7 substrate specificity in histone H2B Protein isoaspartyl impacts on T cell function in lupus Novel PRMT inhibitors for cancer therapy Methionine addiction in osteosarcoma malignancy Major scientific awards: American Chemical Society Ralph F. Hirschmann Award in Peptide Chemistry NIH MERIT Award Ellison Medical Foundation Senior Scholar Award William C. Rose Award, ASBMB UCLA Distinguished Teaching Award (Eby Award winner) Current lab members include PhD candidates Eric Pang (UCSB) and Sining "Cindy" Wang (UCLA), while undergraduates Celeste Medina-Seymoure , Elizabeth Oroudjeva , Olivia Pacheco , and Jasmine Winter contribute to ongoing proteostasis studies. Collaborations with Profs. Jose Rodriguez and Catherine Clarke demonstrate interdisciplinary research approaches.
John D. Murray is the Gregg L. Engles Associate Professor of Psychological and Brain Sciences at Dartmouth College and an Adjunct Associate Professor of Psychiatry at Yale School of Medicine. He holds a PhD in Physics from Yale University (2013) and a BS in Physics and Mathematics from Yale (2006). His research focuses on computational neuroscience and computational psychiatry, with secondary appointments in Physics and Neuroscience at Yale until 2023. His work integrates computational modeling, neuroimaging, and systems neuroscience to study decision-making processes, cortical organization, and psychiatric disorders. Collaborators include prominent researchers like Dr. John Krystal and Dr. Anticevic. Research interests include hierarchical brain organization, neuroimaging analysis techniques, and pharmacological effects on neural circuits. His lab (Murray Lab) develops computational tools like PsychRNN for cognitive task modeling. Notable contributions include linking transcriptomic data to neuroimaging patterns and modeling LSD’s effects on brain topography. He has been featured in YaleNews and Nature Communications for innovations in mapping mental illness variability and neural circuit dynamics. Grants and collaborations span translational neuroscience, addiction, and PTSD research through partnerships with Yale’s Center for Biomedical Data Science and VA National Center for PTSD. His interdisciplinary approach bridges physics, computer science, and clinical psychiatry to advance understanding of brain function and dysfunction.
Cara Lena Crook, PhD, is an Assistant Professor in the Department of Neurology at Yale School of Medicine. She specializes in neuropsychology, focusing on how brain function affects cognition, emotion, and behavior in patients with neurological and psychological conditions. Institution: Yale School of Medicine Department: Neurology Academic Rank: Assistant Professor Dr. Crook earned her PhD in Clinical Neuropsychology from Fordham University, completed her residency at Alpert Medical School of Brown University, and a fellowship at VA Boston Healthcare System, where she advanced her skills in neuropsychological assessment and intervention. Her research and clinical interests center on understanding the neural basis of cognitive and emotional processes. She works at the intersection of neurology and psychology, contributing to patient care, teaching, and scholarly activity in clinical neuropsychology. Though specific publications are not listed, her work likely spans assessment methodologies, cognitive disorders, and brain-behavior relationships in neurological populations. Dr. Crook is actively engaged in the academic and clinical missions at Yale, with no indication of part-time status or retirement. She is not noted as a former staff member and is currently contributing to the department’s educational and research initiatives. PhD: Fordham University, Clinical Neuropsychology (2022) Residency: Alpert Medical School of Brown University, Neuropsychology (2022) Fellowship: VA Boston Healthcare System (2024) She has not been cited as having formal advisees or receiving specific scientific awards in the available text. There is no mention of grants, labs, or research teams she leads, though her fellowship and academic appointments suggest active involvement in clinical research and training.
